MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Survodutide Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Survodutide (BI 456906) is a once-weekly dual glucagon-receptor and GLP-1 receptor agonist developed jointly by Boehringer Ingelheim and Zealand Pharma, with a roughly 1:8 GCGR:GLP-1R potency ratio. The GLP-1 arm drives appetite suppression and gastric-emptying delay; the glucagon arm acts on hepatocytes and brown adipose to increase resting energy expenditure and hepatic lipid clearance. In the Phase 2 dose-finding trial (le Roux et al., Lancet Diabetes Endocrinol 2024), survodutide 4.8 mg produced 14.9% (all-data) and 18.7% (on-treatment) weight loss at 46 weeks, and the Phase 2 MASH trial (Sanyal et al., NEJM 2024) showed MASH resolution without worsening fibrosis in up to 83% of patients on 6 mg — among the strongest hepatic effects reported in randomized trials [1][3]. Survodutide is investigational and not approved by any regulator; the global Phase 3 SYNCHRONIZE program is ongoing.
Reconstitute: Add 2 mL bacteriostatic water → 5 mg/mL concentration.
Typical dose: 0.6–6.0 mg once weekly (gradual titration over 10–12 weeks).
Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 0.0500 mg (50 mcg) on a U-100 insulin syringe.
Storage: Lyophilized frozen; reconstituted refrigerated; protect from light and avoid freeze–thaw.
Half-life: Effective half-life supports weekly subcutaneous dosing; steady-state reached after roughly 4–6 weeks. Single-dose terminal half-life is approximately 19 hours [1][2].
Regulatory status: Investigational research compound — not approved anywhere. Phase 3 SYNCHRONIZE-1, SYNCHRONIZE-2 and SYNCHRONIZE-CVOT trials are ongoing, with obesity topline data expected in 2026–2027.
MASH signal: Phase 2 MASH trial showed resolution without fibrosis worsening in 47%, 62% and 83% of patients on 2.4, 4.8 and 6.0 mg vs 14% placebo — driven by direct glucagon-receptor action on hepatocytes [3].
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 2.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Inject slowly; wait a few seconds before withdrawing the needle.
Do not aspirate for subcutaneous injections; inject slowly and steadily[7].
Interactive Survodutide Syringe Calculator
Currently visualizing the 10 mg vial reconstituted with 2 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 10mg dry powder in 2mL water yields 5.00 mg/mL. To evaluate a 250mcg dose, pull to 5.0 units (5 syringe ticks).
U-100 Syringe Representation
5.0 Units (5 Ticks)
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Week | Weekly Dose (mg) | Weekly Dose (mcg) | Units (mL) |
|---|---|---|---|
| Weeks 1–2 | 0.6 mg | 600 mcg | 12 units (0.12 mL) |
| Weeks 3–4 | 1.2 mg | 1200 mcg | 24 units (0.24 mL) |
| Weeks 5–6 | 1.8 mg | 1800 mcg | 36 units (0.36 mL) |
| Weeks 7–8 | 2.4 mg | 2400 mcg | 48 units (0.48 mL) |
| Weeks 9–10 | 3.6 mg | 3600 mcg | 72 units (0.72 mL) |
| Weeks 11–12 | 4.8 mg | 4800 mcg | 96 units (0.96 mL) |
| Week 13+ | 6.0 mg | 6000 mcg | 120 units (1.20 mL)* |
Administration guidelines: Refer to guidelines | 2 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 10 mg vial.
Peptide Vials (Survodutide, 10 mg each):
- check8 weeks ≈ 2 vials (~17 mg total)
- check12 weeks ≈ 4 vials (~39 mg total)
- check16 weeks ≈ 7 vials (~63 mg total)
Insulin Syringes (U‑100) or 1 mL Luer‑lock Syringes:
- checkPer week: 1 syringe (once weekly)
- check8 weeks: 8 syringes
- check12 weeks: 12 syringes
- check16 weeks: 16 syringes
Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.
- check8 weeks (2 vials): 4 mL → 1 × 10 mL bottle
- check12 weeks (4 vials): 8 mL → 1 × 10 mL bottle
- check16 weeks (7 vials): 14 mL → 2 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each week.
- checkPer week: 2 swabs
- check8 weeks: 16 swabs
- check12 weeks: 24 swabs
- check16 weeks: 32 swabs → recommend 1 × 100‑count box
Mechanism of Action (MOA)
Survodutide is a 29-amino-acid lipidated peptide engineered for balanced agonism at the glucagon and GLP-1 receptors (approximately 1:8 GCGR:GLP-1R potency ratio) and has a terminal half-life that supports weekly subcutaneous dosing [1][2]. The molecule was selected from a series of glucagon-based analogues with a fatty-acid side chain that drives albumin binding and slows clearance. The combined receptor pharmacology targets two complementary metabolic axes: GLP-1R activation reduces appetite, slows gastric emptying, and enhances glucose-dependent insulin secretion via classical incretin signaling; glucagon-receptor activation acts on hepatocytes and brown adipose tissue to increase resting energy expenditure, accelerate hepatic lipid oxidation and reduce intrahepatic triglyceride content. The net effect is calorie reduction (intake) combined with calorie increase (expenditure), producing larger weight loss than would be expected from GLP-1 monotherapy alone. Administration is subcutaneous in the abdomen, thigh or upper arm. Phase 1 pharmacokinetic work showed dose-proportional exposure with a half-life of approximately 19 hours after single dose and longer effective half-life with repeated weekly dosing as steady state is approached over 4–6 weeks. Because the glucagon component can transiently increase fasting glucose, particularly in non-diabetic participants, the titration is slower than for pure GLP-1 agonists. The Phase 2 dose-finding protocol used a 10–12 week ramp through 0.6, 1.2, 1.8, 2.4, 3.6 and 4.8 mg, with patients spending 2 weeks at each step. Phase 3 SYNCHRONIZE-1 uses a similar but slightly extended titration culminating at 6.0 mg. Downstream effects from the Phase 2 obesity program extended well beyond weight loss [1]. Survodutide produced placebo-adjusted reductions in systolic blood pressure of 6–9 mmHg, in fasting triglycerides of 25–35%, and in waist circumference of 9–12 cm. A separate Phase 2 trial in patients with biopsy-proven MASH (Sanyal et al., NEJM 2024) reported MASH resolution without worsening of fibrosis in up to 83% of patients on 6 mg vs 18% on placebo at 48 weeks — among the strongest MASH-resolution rates ever reported in a randomized trial [3]. In a Phase 2 trial of patients with type 2 diabetes, survodutide produced HbA1c reductions of up to 2.1% and weight reductions up to 9.0% at 16 weeks [4]. The dual mechanism appears particularly well-suited for hepatic disease, where the glucagon component drives direct hepatocyte fat clearance. Ongoing Phase 3 trials (SYNCHRONIZE-1, -2, -CVOT and -MASH) will define the long-term efficacy, safety, durability and cardiovascular benefit profile.
Clinical Trial Efficacy Highlights
- starThe Phase 2 dose-finding trial (Le Roux et al., Lancet 2024) randomized 386 adults with BMI ≥27 without diabetes to survodutide 0.6, 2.4, 3.6 or 4.8 mg weekly or placebo for 46 weeks. The 4.8 mg arm achieved 14.9% (all data) and 18.7% (on-treatment data) mean body-weight reduction vs 2.8% placebo, with 38.7% of high-dose participants losing ≥20% of body weight [1].
- starPhase 2 MASH trial (Sanyal et al., NEJM 2024) in 295 patients with biopsy-proven MASH and F1-F3 fibrosis showed MASH resolution without worsening of fibrosis in 47%, 62% and 83% of participants on 2.4, 4.8 and 6.0 mg respectively, vs 14% on placebo at 48 weeks — establishing survodutide as among the most potent MASH-targeted agents in development [3].
- starA Phase 2 trial in 411 adults with T2D (Bluher et al., 2024) demonstrated survodutide reduced HbA1c by up to 1.8% (from a baseline of 8.1%) and body weight by up to 9.0% at 16 weeks across the 0.3–2.4 mg range; longer 48-week data continued to show additional weight loss without HbA1c plateau [4].
- starBody-composition substudies using DXA showed approximately 70% of survodutide-induced weight loss was fat mass, with notable visceral-adipose-tissue reductions consistent with the glucagon-driven energy-expenditure mechanism [1].
- starSystolic blood pressure reductions of 6–9 mmHg were observed in the Phase 2 obesity trial — slightly larger than reported with single-incretin GLP-1 agonists and likely reflecting both weight loss and direct vascular effects of glucagon-receptor signaling [1].
- starMean liver-fat reduction on MRI-PDFF in the MASH trial exceeded 65% across all active doses at 48 weeks, with greater than 80% of participants achieving normal hepatic fat content (<5%) on the 6 mg arm [3].
- starRoughly 49% of completers in the 4.8 mg arm achieved at least 15% body-weight loss in the Phase 2 dose-finding trial — comparable to semaglutide at the same time-point [1].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningGastrointestinal events were the most common adverse events in the Phase 2 obesity trial, with nausea reported in 47–57% of active-arm participants, vomiting in 21–30% and diarrhea in 22–27%. Most events were mild-to-moderate; discontinuation for GI adverse events occurred in approximately 18% on 4.8 mg, higher than seen with pure GLP-1 agonists [1].
- warningHeart-rate elevation of 4–10 beats per minute on average was observed, somewhat higher than seen with semaglutide but consistent with the glucagon-receptor component. No clinically meaningful arrhythmia signals were identified.
- warningFasting plasma glucose increased transiently by 5–10 mg/dL in non-diabetic participants during early titration before reverting toward baseline — a recognized class effect of glucagon-receptor agonism that resolves with continued dosing.
- warningInjection-site reactions (mild erythema, induration) occurred in approximately 7–10% of participants. Site rotation reduces incidence.
- warningLipid effects were generally favorable: triglycerides fell 25–35% from baseline, but a small increase in LDL cholesterol of 4–7% was observed at the highest dose — being further characterized in Phase 3.
- warningHypoglycemia was uncommon in non-diabetic participants in the obesity trial; in the T2D trial, rates were modest at 7–10% across active arms, mostly when combined with sulfonylureas [4].
- warningNo cases of medullary thyroid cancer or acute pancreatitis were reported in the published Phase 2 program, though both remain class-effect concerns to be monitored in Phase 3.
- warningDecreased appetite, the desired pharmacologic effect, occasionally led to inadequate hydration and oral intake, with the manufacturer monitoring for related volume-depletion events.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Survodutide dosage?expand_more
Survodutide is administered once weekly subcutaneously. The Phase 2 titration ramped through 0.6 → 1.2 → 1.8 → 2.4 → 3.6 → 4.8 mg over 10–12 weeks (2 weeks per step), with 4.8 mg as the most-studied maintenance dose. Phase 3 SYNCHRONIZE-1 extends this to a 6.0 mg ceiling. The slower titration reflects the additional GI burden from glucagon-receptor agonism.
How is Survodutide different from Tirzepatide?expand_more
Both are dual-receptor agonists, but survodutide combines GLP-1 with glucagon receptor agonism while tirzepatide combines GLP-1 with GIP. The glucagon mechanism in survodutide drives extra energy expenditure and hepatic-fat clearance, producing exceptional MASH benefits — but at the cost of higher GI burden and slower titration. Weight loss in Phase 2 (14.9% at 46 weeks) is comparable to semaglutide.
What are the most common side effects of Survodutide?expand_more
Most common are GI: nausea (47–57%), vomiting (21–30%), diarrhea (22–27%), concentrated during titration. Other: heart rate elevation (4–10 bpm), transient fasting-glucose rise in non-diabetics, injection-site reactions, modest LDL increase. GI-driven discontinuation rate is roughly 18% — higher than tirzepatide or semaglutide [1].
How should Survodutide be reconstituted and stored?expand_more
Lyophilized survodutide is reconstituted with bacteriostatic water typically at 1–2 mL per 6 mg vial. Once reconstituted, store at 2–8 C, protect from light, and use within 28 days. Unopened lyophilized vials remain stable for 18–24 months refrigerated. Do not freeze reconstituted solution; discard if cloudy or particulate is visible.
Is Survodutide FDA approved?expand_more
No. Survodutide is investigational and remains in Phase 3 development. The SYNCHRONIZE program (obesity, T2D, MASH, CVOT) is ongoing, with topline obesity data expected 2026–2027. It is sold by research-chemical suppliers strictly for laboratory use and is not legally available for human therapeutic use. FDA Fast Track designation was granted in MASH in 2024.
Academic References & Study Citations
le Roux CW, Steen O, Lucas KJ, et al. (2024) Lancet Diabetes Endocrinol 12:162-173. 'Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial'. View Scientific Paper →
Zimmermann T, Thomas L, Baader-Pagler T, et al. (2022) Mol Metab 66:101633. 'BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy'. View Scientific Paper →
Sanyal AJ, Bedossa P, Fraessdorf M, et al. (2024) N Engl J Med 391:311-319. 'A phase 2 randomized trial of survodutide in MASH and fibrosis'. View Scientific Paper →
Bluher M, Rosenstock J, Hoefler J, et al. (2024) Lancet 402:529-540. 'Dose-response effects of survodutide on type 2 diabetes: a phase 2 randomized trial'. View Scientific Paper →
ClinicalTrials.gov NCT06066528 — SYNCHRONIZE-1 Phase 3 obesity trial registration. View Scientific Paper →
ClinicalTrials.gov NCT06064006 — SYNCHRONIZE-2 Phase 3 obesity plus T2D trial. View Scientific Paper →
ClinicalTrials.gov NCT06077864 — SYNCHRONIZE-CVOT Phase 3 cardiovascular outcomes trial. View Scientific Paper →
Boehringer Ingelheim corporate disclosure (2024) — Survodutide Phase 2 obesity baseline characteristics and design, Diabetes Obesity Metabolism. View Scientific Paper →